Global healthcare company developing medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.
Profile & Fundamentals
Abbott Laboratories: Company identity, ownership, reported financial performance, balance sheets, and corporate actions.
Profile & Fundamentals
Abbott Laboratories Profile & Fundamentals
Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.
Explore this pageJump to a Profile & Fundamentals section
Explore this research
Profile & Fundamentals contents
Jump directly to any section
Company and Market Context
Company Profile & Ownership
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Company profile record
Abbott Laboratories
Common Stock · Health Care · Health Care Equipment
Company
- Company / asset
- Abbott Laboratories
- Security type
- Common Stock
- Sector
- Health Care
- Industry
- Health Care Equipment
- HQ
- 🇺🇸 United States
- Head office
- 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400
Leadership & scale
- Chief executive
- Mr. Robert B. Ford
- CEO year born
- 1974
- Full-time employees
- 122K
- Fiscal year end
- December
- IPO date
- 1978-01-13
Fundamentals snapshot
- Market Cap
- USD 178.8B
- P/E
- 33.0x
- Revenue (Q2 26)
- USD 12.6B
- Profit (Q2 26)
- USD 928.0M
- Dividend Yield
- 1.7%
- Revenue (FY 25)
- USD 44.3B
- Shares in public float
- 1.7B
- Insider ownership
- 0.5%
Reporting & identifiers
- Symbol
- ABT.NYSE
- Listing
- 🇺🇸 United States | Dividend Tax: 30%
- Ticker Currency
- USD
- Income Statement Currency
- USD
- Balance Sheet Currency
- USD
- Cash Flow Currency
- USD
- EPS Currency
- USD
- Contract Type
- SPOT
- ISIN
- US0028241000
- Asset ID
- equity_90606491-6d1d-54e4-989e-78da2d2dbfa6
Ownership
Shares Outstanding
- Shares outstanding
Top holders
- BlackRock Inc145,687,458 shares · 8.42% · Reported 2026-03-31
- Vanguard Capital Management, LLC112,949,933 shares · 6.53% · Reported 2026-03-31
- State Street Corp79,575,468 shares · 4.60% · Reported 2026-03-31
- Vanguard MStar Total Stk Mkt Idx Invest55,464,156 shares · 3.21% · Reported 2026-07-31
- Vanguard Portfolio Management, LLC47,944,891 shares · 2.77% · Reported 2026-03-31
- Schwab US Dividend Equity ETF™47,574,842 shares · 2.75% · Reported 2026-08-29
- Vanguard 500 Index Investor45,726,842 shares · 2.64% · Reported 2026-07-31
View more holders (8)
- Charles Schwab Investment Management Inc45,500,055 shares · 2.63% · Reported 2026-03-31
- Geode Capital Management, LLC39,148,795 shares · 2.26% · Reported 2026-03-31
- Capital Research Global Investors36,908,990 shares · 2.13% · Reported 2026-06-30
- Capital Research & Mgmt Co - Division 334,654,113 shares · 2.00% · Reported 2026-06-30
- Morgan Stanley - Brokerage Accounts30,101,596 shares · 1.74% · Reported 2026-03-31
- JPMorgan Chase & Co26,767,099 shares · 1.55% · Reported 2026-03-31
- NORGES BANK23,354,911 shares · 1.35% · Reported 2026-06-30
- iShares Core S&P 500 ETF23,201,902 shares · 1.34% · Reported 2026-08-31
Earnings, Profitability & Valuation
Earnings & Revenue
Revenue, Net Income, and Free Cash Flow
- Revenue
- Free cash flow
- Net income
Valuation
Historical P/E Ratio
- Published P/E
Profitability & Margins
Profitability Margins
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
Complete Research Workspace
Unlock the complete Profile & Fundamentals
Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.